---
title: "For Sponsors — Amavita Research"
url: https://md.amavitaresearch.com/sponsors
canonical: https://www.amavitaresearch.com/sponsors
schema_type: WebPage
last_updated: 2026-05-12
---

# For Sponsors — Amavita Research

Amavita Research is a Miami-based cardiovascular clinical research site purpose-built for first-in-human, feasibility, and pivotal cardiovascular trials. Sponsors choose Amavita Research for three reasons:

## 1. In-house patient flow

Amavita Research is the clinical-research arm of amavita Heart and Vascular Health® — the largest independent cardiovascular practice in South Florida. Trial-eligible patients walk into the practice for routine cardiology care every business day and are screened against active trial inclusion criteria in real time by the same physicians who serve as Principal Investigators. This in-house patient flow is structural, not circumstantial, and competing Miami sites without a parent cardiology practice cannot replicate it.

## 2. Speed and predictability

- 5–8 weeks contract-to-first-patient for trial types Amavita is already qualified at
- 6–10 weeks screening-to-enrolled conversion for a typical 20-patient cardiovascular feasibility study
- Weekly KPI dashboards via Monday.com (screened, consented, enrolled vs. target)
- Zero FDA inspection findings to date

## 3. Quality and cost

- IAOCR GCSA-certified site
- ICH-GCP E6(R3) compliant SOPs
- SCRS member
- 20–30% lower cost than high-end private-equity-backed Miami site networks
- Sponsor retains full data, IP, protocol ownership

## Therapeutic areas

Structural heart, coronary revascularization and high-risk PCI, electrophysiology, heart failure, peripheral artery disease, cardiogenic shock, pulmonary embolism response, and adjacent interventional cardiology indications.

## How to engage

Email srubio@amavita.health or use https://www.amavitaresearch.com/contact-sponsor. First conversation is a 30-minute feasibility call. Response within one business day. Under MNDA we share investigator CVs, site qualification packets, and prior-trial enrollment metrics.

## Hybrid US + Latin America trial designs

Amavita Research integrates with sister organization bioaccess® (Latin America first-in-human CRO). Sponsors can run a US arm at Amavita and a Latin American arm at bioaccess under the same protocol — FDA-ready data on both sides, single sponsor relationship, accelerated total enrollment.

See the full sponsor FAQ: https://www.amavitaresearch.com/faq-sponsors